Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
0.7351
+0.0121 (1.67%)
At close: Jul 3, 2025, 1:00 PM
0.7500
+0.0149 (2.03%)
After-hours: Jul 3, 2025, 4:47 PM EDT
Invivyd Revenue
Invivyd had revenue of $11.30M in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $36.69M. In the year 2024, Invivyd had annual revenue of $25.38M.
Revenue (ttm)
$36.69M
Revenue Growth
n/a
P/S Ratio
2.40
Revenue / Employee
$366,880
Employees
100
Market Cap
88.18M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25.38M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
IVVD News
- 4 days ago - Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome - GlobeNewsWire
- 10 days ago - Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection - GlobeNewsWire
- 5 weeks ago - Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus - GlobeNewsWire
- 6 weeks ago - Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas - GlobeNewsWire
- 6 weeks ago - Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19 - GlobeNewsWire
- 7 weeks ago - Invivyd, Inc. (IVVD) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 7 weeks ago - Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy - GlobeNewsWire